JP Morgan Chase’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-228,900
Closed -$9M – 7883
2023
Q2
$9M Buy
228,900
+222,200
+3,316% +$7.84M ﹤0.01% 2372
2023
Q1
$163K Buy
+6,700
New +$147K ﹤0.01% 5178

JP Morgan Chase's ISEE Position: Q3 2023 in Review

JP Morgan Chase sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 403,077 shares — an estimated $15.9M sold.

JP Morgan Chase first reported a position in ISEE in Q4 2013 and held it in 37 quarters. The position peaked at $19M in Q1 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.

  • JP Morgan Chase reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 403,077 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $15.9M.
  • JP Morgan Chase first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 37 quarters.
  • JP Morgan Chase's IVERIC bio, Inc. Common Stock position peaked at $19M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.